Image

MEA CAR-T Cell Therapy Treatment Market – Industry Trends and Forecast to 2031

Pharmaceutical

Image

MEA CAR-T Cell Therapy Treatment Market – Industry Trends and Forecast to 2031

  • Pharmaceutical
  • Published Report
  • Apr 2024
  • MEA
  • 350 Pages
  • No of Tables: 119
  • No of Figures: 59

MEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others)- Industry Trends and Forecast to 2031.

MEA CAR-T Cell Therapy Treatment Market

MEA CAR-T Cell Therapy Treatment Market Analysis and Size     

The rising prevalence of cancer in the MEA region is a key driver for the Car-T cell therapy treatment market, creating a growing need for more effective treatments. However, the high cost of Car-T cell therapy presents a significant barrier, potentially limiting its accessibility. On the bright side, there is an opportunity for market growth through the region's increasing focus on healthcare infrastructure development and medical tourism, particularly in countries like Singapore. Nevertheless, a major challenge is the requirement for extensive Research and clinical trials to establish the long-term efficacy and safety of Car-T cell therapy in this region.    

MEA CAR-T Cell Therapy Treatment MarketMEA CAR-T Cell Therapy Treatment Market

Data Bridge Market Research analyzes that the MEA CAR-T cell therapy treatment market is expected to reach USD 105.69 million by 2031, growing at a CAGR of 30.7% in the forecast period of 2027 to 2031.    

Report Metric

Details

Forecast Period

2027 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016–2021)

Quantitative Units

Revenue in USD Million

Segments Covered

Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others)        

Countries Covered

Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and Rest of Middle East and Africa

Market Players Covered

Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc., among others

Market Definition

CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. These receptors are chimeric because they are combined with both antigen-binding and T-cell activating functions into a single receptor. Once the CAR-T cells infused in the patient’s body then they act as a “living cell” which has the ability or designed in such a way that they can kill the harmful cancer cells without affecting the healthy cells. The CAR-T cells when comes in contact with the targeted antigen on a cell, CAR-T cells binds with it and becomes activated and multiply to become cytotoxic.

MEA CAR-T Cell Therapy Treatment Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Increasing Prevalence of Cancer and other Target Diseases      

Cancer is a leading cause of morbidity and mortality worldwide, and the incidence of cancer is rising in these regions due to factors such as population growth, aging, and lifestyle changes. Additionally, there is a growing burden of other target diseases, such as hematological disorders, which can also be treated with CAR-T cell therapy. This increasing disease burden underscores the need for innovative and effective treatments like CAR-T cell therapy, driving market growth.

  • Growing Awareness and Acceptance of Car-T Cell Therapy

The growing awareness and acceptance of CAR-T cell therapy as an effective treatment in the MEA, Saudi Arabia, and MEA regions are driven by various factors. These include heightened media coverage, educational efforts by healthcare organizations, and the sharing of success stories that highlight the therapy's effectiveness. Consequently, patients and healthcare providers are gaining a better understanding of CAR-T cell therapy's potential advantages, such as higher response rates and long-lasting remissions, especially in cases that are refractory or have relapsed. Additionally, regulatory approvals and endorsements in these regions have cemented CAR-T cell therapy's status as a legitimate and viable treatment option.

MEA CAR-T Cell Therapy Treatment Market

Opportunity

  • The Extensive Pipeline of Car-T Cell Therapy

The extensive pipeline represents a wealth of opportunities for patients, healthcare providers, and the healthcare industry as a whole. This pipeline includes a range of CAR-T cell therapy products in various stages of development, from early preclinical Research to advanced clinical trials. The pipeline reflects ongoing innovation and investment in CAR-T cell therapy, with new products being developed to target different types of cancer and hematological disorders. Additionally, the pipeline includes products aimed at improving the safety, efficacy, and accessibility of CAR-T cell therapy, such as next-generation CAR-T cell therapies and off-the-shelf CAR-T cell products.

Restraints/Challenges

  • High Cost of Car-T Cell Therapy

CAR-T cell therapy is a highly personalized and complex treatment that involves modifying a patient's immune cells to target cancer cells, making it a costly procedure. Factors contributing to this high cost include the specialized manufacturing process, extensive clinical monitoring, and infrastructure requirements. As a result, many patients, particularly those without adequate insurance coverage or financial resources, face challenges accessing this innovative therapy. The cost of clinical trials, regulatory compliance, and post-treatment monitoring further increases the overall expense, highlighting the financial burden for patients, especially those from lower-income backgrounds.

  • Potential Risks and Adverse Effects of Treatment

CAR-T cell therapy, despite its promising efficacy, presents potential risks and side effects that pose challenges for patients and healthcare providers in the MEA, Saudi Arabia, and MEA regions. The most common side effects include cytokine release syndrome (CRS) and neurotoxicity. CRS, a significant adverse effect, occurs when infused CAR T cells recognize and attack cancer cells, leading to the release of cytokines like interleukin-6 (IL-6). This immune response causes systemic inflammation, manifesting in symptoms from mild fever and flu-like symptoms to potentially life-threatening complications like hypotension, respiratory distress, and multiorgan failure. CAR T-cell therapy can also trigger immune effector cell-associated neurotoxicity syndrome (ICANS), characterized by neurological symptoms such as confusion, seizures, and impaired speech. These side effects result from immune system overactivation and cytokine release, emphasizing the need for vigilant monitoring and prompt management to ensure patient safety and treatment efficacy.

Recent Developments

  • In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy
  • In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio
  • In February 2022, the FDA has approved CARVYKTI™ (ciltacabtagene autoleucel) from Janssen for treating adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, marking Janssen's inaugural cell therapy. This will underscore the dedication to advance their oncology treatment options
  • In December 2021, Novartis AG has signed an agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), enhancing the company's immuno-oncology Research and development. This collaboration contributes to Novartis Oncology's broader initiative to advance innovation in cancer treatments by incorporating a potentially transformative therapy into its expanding immunotherapy platform

MEA CAR-T Cell Therapy Treatment Market Scope   

The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product

  • Autologous CAR-T Cells
  • Allogeneic CAR-T Cells

On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells.

Structure

  • First Generation CAR-T Cells
  • Second Generation CAR-T Cells
  • Third Generation CAR-T Cells
  • Fourth Generation CAR-T Cells 

On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells.

Targeted Antigens

  • Antigens on Solid Tumors
  • Antigens on Hematologic Malignancies
  • Others  

On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others. 

Brand

  • Yescarta
  • Kymriah
  • Tecartus
  • Others 

On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others.

Therapeutic Application

  • Hematological Malignancies
  • Pancreatic Cancer
  • Breast Cancer
  • Lung Cancer
  • Gastric Cancer
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Others      

On the basis of therapeutic application, the market is segmented into diffuse large b-cell lymphoma, follicular lymphoma, Acute Lymphoblastic Leukaemia (ALL), mantle cell lymphoma, multiple myeloma, hematologic malignancies, lung cancer, chronic lymphocytic leukemia, gastric cancer, pancreatic cancer, breast cancer, and others.   

End User

  • Hospitals
  • Specialty Clinics
  • Others

On the basis of end user, the market is segmented into hospitals, specialty clinics and others. 

Distribution Channel

  • Hospitals Pharmacy
  • Others

On the basis of distribution channel, the market is segmented into hospitals pharmacy and others.

MEA CAR-T Cell Therapy Treatment Market

MEA CAR-T Cell Therapy Treatment Market Regional Analysis/Insights

The MEA CAR-T cell therapy treatment market is segmented into seven notable segments based on product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel.

The countries covered in this market report are Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East and Africa.

Saudi Arabia is expected to dominate the MEA CAR-T cell therapy treatment market due to its advanced healthcare infrastructure, government support, growing medical tourism sector, research and development activities, and increasing demand for advanced treatments.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and MEA CAR-T Cell Therapy Treatment Market Share Analysis 

The MEA CAR-T cell therapy treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.  

Some of the major market players operating in the market are Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc., among others.  


SKU-

TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA)

TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)

TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)

TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)

TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)

TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)

TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)

TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)

TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)

TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)

TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)

TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The MEA CAR-T Cell Therapy Treatment Market size will be worth USD 105.69 million by 2031.
The MEA CAR-T Cell Therapy Treatment Market growth rate will be 30.7% by 2031.
The Increasing Prevalence of Cancer and other Target Diseases, Growing Awareness and Acceptance of Car-T Cell Therapy are the growth drivers of the MEA CAR-T Cell Therapy Treatment Marke
The product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel are the factors on which the MEA CAR-T Cell Therapy Treatment Market research is based.
The major companies in the MEA CAR-T Cell Therapy Treatment Market are Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Services, Inc. etc
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials